We assessed the clinical utility of next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in a uniformly treated cohort of 79 patients with paediatric B-cell acute lymphoblastic leukaemia. Bone marrow samples were collected at the time of diagnosis, days 33 and 80, pre-(4-5 months) and post-(24 months) maintenance therapy time points, and at relapse. We identified leukaemia-specific CDR3 sequences in 72 of 79 patients (91%) and detected MRD in 59 of 232 samples. Although MRD was detected in 28 of 55 samples (51%) on day 33, the frequencies of MRD detection decreased to 25% (16/65) at day 80, 19% (11/58) at 4-5 months and 7Á4% (4/54) at 24 months. In a univariate analysis, positive MRD results on day 80 [relative risk (RR) 95% confidence interval (CI) = 7Á438 (2Á561-21Á6), P < 0Á001], at 4-5 months [RR (95% CI) = 10Á24 (3Á374-31Á06), P < 0Á001], and at 24 months [RR (95% CI) = 19Á26 (4Á974-74Á59), P < 0Á001] exhibited statistically significant associations with inferior leukaemia-free survival; this was confirmed using a Cox proportional hazard model. Our study suggests the promising potential of NGS-MRD for patients with B-cell ALL.
The prognosis of children with B-cell acute lymphoblastic leukaemia (B-cell ALL) has dramatically improved over the past three decades to the current overall survival rate of 90% (Hunger et al, 2012; Pui et al, 2012) . The introduction of minimal residual disease (MRD) monitoring to refine disease risk stratification was among the most important advances in this field (Cave et al, 1998; Coustan-Smith et al, 1998; van Dongen et al, 1998) . MRD-based treatment intensification has led to improved clinical outcomes (Yeoh et al, 2012; Vora et al, 2014; Pui et al, 2015) .
At present, both flow cytometry (FCM) and real-time quantitative polymerase chain reaction (RQ-PCR) are widely used for MRD monitoring. Although both methods yield highly consistent results with sensitivities of 10 À4 , each method has several limitations. For example, RQ-PCR is time consuming and laborious: the immunoglobulin and T-cell receptor (TCR) gene rearrangements at diagnosis and the design of corresponding primers can take 3-4 weeks. In addition, the evolution of additional clones beyond the first or index clone during therapy cannot be detected, which might cause false-negative results. FCM requires experienced technicians and sometimes does not achieve a sensitivity of 10 À4 (Gaipa et al, 2012; Schrappe, 2012; van Dongen et al, 2015) . Accordingly, a next generation sequencing (NGS)-based method has been developed in an attempt to overcome these limitations (Faham et al, 2012; Logan et al, 2013 Logan et al, , 2014 Ladetto et al, 2014; Wu et al, 2014; Pulsipher et al, 2015) . However, the number of published studies that have tested the clinical utility of this novel method is very scarce (Wu et al, 2014; Kotrova et al, 2015; Pulsipher et al, 2015) . The NGS method uses a set of universal primers, thus avoiding the laborious processes of primer designing and testing of patient-specific rearrangements. Moreover, this method has a higher sensitivity than other methods, with sensitivity values approaching 10 À6 , which may allow more accurate predictions of clinical outcomes. In this study, we addressed the clinical utility of NGS-MRD at several time points in a uniformly treated cohort of patients with paediatric B-cell ALL.
Patients and methods

Patients
We enrolled 79 patients with paediatric B-cell ALL who were treated at two hospitals between April 2002 and November 2014; all patients were treated according to the Japan Association of Childhood Leukaemia Study (JACLS) ALL-02 protocol (Suzuki et al, 2010; Hasegawa et al, 2011) , which did not incorporate the MRD status into its risk stratification ( Figure S1 ). Samples were collected at the time of diagnosis, on days 33 and 80, at the times of maintenance therapy initiation (4-5 months) and completion (24 months), and at relapse. Written informed consent was obtained from the patients or their parents. The ethics committee of Nagoya University Graduate School of Medicine approved this study.
DNA extraction
Genomic DNA was extracted from frozen bone marrow mononuclear cells using a QIAamp DNA Blood Mini Kit or an AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany). Quantification was performed using a Qubit 2.0 Fluorometer and Qubit dsDNA HS Assay Kit (Life Technologies, Carlsbad, CA, USA).
Polymerase chain reaction
Polymerase chain reaction amplification of the IGH and the TRG locus complementarity-determining region 3 (CDR3) was performed as previously described Faham et al, 2012) . Briefly, a two-step PCR was performed. For the second PCR step, the 5 0 -end of each primer used in the first step was tagged with a universal scaffold sequence (Table SI) . A total of 3200 ng of genomic DNA was mixed in a 100:1 ratio with spike-in reference DNA containing a known CDR3 sequence. The prepared DNA was then amplified using multiplexed primers and PrimeSTAR GXL DNA Polymerase (Takara Bio, Otsu, Japan). In the second PCR step, the PCR product was given an individual index and adaptor sequences for NGS.
Sanger sequencing
Direct PCR product sequencing was performed using the BigDye Terminator v3.1 Cycle Sequencing Kit and an ABI PRISM 3130xl Genetic Analyser (Life Technologies).
Next-generation sequencing
The final PCR product was multiplexed and purified using Agencourt AMPure XP beads (Beckman Coulter, Brea, CA, USA). The prepared library was quantified using a Qubit 2.0 Fluorometer and an Agilent 2200 TapeStation (Agilent, Santa Clara, CA, USA). After quantification, NGS was performed using a MiSeq next-generation sequencer and MiSeq Reagent Kit v3 (600-cycle; Illumina, San Diego, CA, USA) with 2 9 150-base pair (bp) paired end reads. For each sample, approximately two million reads were obtained to detect a clonotype from a single cell with ≥3 reads, which yielded a false negative rate <0Á05 based on a binomial distribution. A run was accepted if ≥80% of the total bases were of good quality (Q30).
Determination of leukaemia-specific CDR3 sequences
For 13 patients, Sanger sequencing was used to determine leukaemia-specific CDR3 sequences in the IGH locus. Briefly, 22 PCR reactions were performed using a V region-specific primer for each of these patients. PCR products were run on an agarose gel, and samples with the correct product size were directly sequenced. For the other patients, the IGH locus was assessed via multiplex PCR and subsequent NGS. We defined a leukaemia-specific CDR3 sequence as a specific CDR3 sequence that was detected in >5Á0% of all sequence reads. For patients without any leukaemia-specific CDR3 sequences, we assessed the TRG locus. A cut-off level of 5% was used for the TRG locus. All sequences were evaluated using IMGT V-QUEST software (Brochet et al, 2008; Giudicelli et al, 2011) .
Detection of leukaemia-specific CDR3 sequences and calculation of NGS-MRD Using our in-house computational program, we tested whether each obtained read contained a sequence that was completely identical to the leukaemia-specific CDR3 sequence. Reads with inadequate quality (containing an unidentified base or an adaptor sequence) were discarded. We considered the result positive for NGS-MRD if the leukaemia-specific CDR3 sequence was detected in a read. The NGS-MRD level was calculated based on the ratio of reads containing the tumour and reference CDR3 sequences. We categorized positive MRD results as low positive when the positivity rate was <10 À4 and high positive when this rate was ≥10 À4 . Sensitivity was quantitatively tested by mixing control DNA from healthy volunteers with a known amount of tumour-derived DNA.
To detect clonal evolution, we determined the frequency of each CDR3 sequence at each time point. If a novel CDR3 sequence was present at a frequency >5%, we considered it to be a new leukaemia-specific CDR3 sequence that had emerged via clonal evolution. Minimal residual disease risk classification was determined according to the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)-Berlin-Frankfurt-Munster (BFM) protocol (Flohr et al, 2008 
RQ-PCR-based detection of MRD
Real-time PCR on the CDR3 of the IGH locus was performed essentially as previously described (Nakao et al, 2000; van der Velden et al, 2003) . Briefly, we designed primer sets amplifying 70-170 bp of tumour-specific CDR3 sequences. Using the primers, a SYBR Premix Ex Taq II kit (TaKaRa Bio, Otsu, Japan) and an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA), we performed allele-specific oligonucleotide-PCR according to the manufacturers' instructions. Primer sequences are available upon request.
Statistical analysis
For statistical analyses of the clinical parameters and NGS-MRD results, Fisher's exact test was used for categorical variables, and the Mann-Whitney U test was used for continuous variables. The probability of leukaemia-free survival (LFS) was calculated using the Kaplan-Meier method and log-rank test, in which relapse was treated as an event and both death without relapse and haematopoietic stem cell transplantation (HSCT) were censored. The cumulative incidence of relapse (CIR) was assessed using the Gray test. A Cox proportional hazard model was used for the univariate and multivariate LFS analyses. The following covariates were evaluated: patient age, sex, National Cancer Institute (NCI) risk stratification, prednisolone response, and NGS-MRD status at each time point. All statistical analyses were performed using EZR (Saitama Medical Centre, Jichi Medical University), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) (Kanda, 2013) .
Results
Patient characteristics
We retrospectively analysed 79 patients with paediatric B-cell ALL who were treated according to the JACLS ALL-02 protocol (Table I, Figure S1 ). Patients with infantile B-cell ALL (age <1 year) and KMT2A (MLL) rearrangement were excluded from this study. The median age in our cohort was 5Á4 years (range: 0Á9-15Á4 years). The median observation period was 6Á4 years (range: 0Á1-12Á4 years). During the study period, 19 patients relapsed, and the 5-year CIR [95% confidential interval (CI)] was 24Á5% (14Á9-35Á4%). Eighteen of the 19 relapsed patients received HSCT, and 13 remained alive and well. Overall, the 5-year LFS (95% CI) was 72Á9% (32Á3-91Á6%), and the 5-year overall survival (OS) (95% CI) was 96Á2% (88Á6-98Á7%).
CDR3 detection and NGS-MRD measurement
Using Sanger sequencing or NGS, we investigated leukaemiaspecific CDR3 sequences in the IGH or TRG locus in diagnostic samples. At least one leukaemia-specific CDR3 sequence was detected in 72 of the 79 patients (91%) ( Table SII) .
We confirmed the sensitivity and quantitativity of our NGS-MRD detection system using test samples containing known amounts of leukaemic cells ( Figure S2A ). Our system was found to have an MRD detection sensitivity of 10 À6 and linear quantification. We also assessed the reproducibility ( Figure S2B ) and correlation with RQ-PCR-based detection ( Figure S2C ). We measured MRD in a total of 232 samples and identified positive results in 59 samples ( Figure S3 ). Of these, 32 and 27 samples (14% and 12%) were considered to be low positive (<10 À4 ) and high positive (≥10 À4 ), respectively.
Although we detected MRD in 51% (28/55) of patients at day 33, the frequencies of positive MRD decreased to 25% (16/65) at day 80, 19% (11/58) at 4-5 months and 7Á4% (4/ 54) at 24 months (Table I) . We classified 50 patients for whom both day 33 and day 80 results were available into SR, IR and HR groups. Only one patient was classified as MRD-HR. Using results with a sensitivity of 10 À4 , 38 patients were classified as MRD-SR and 11 were classified as MRD-IR. The 5-year LFS did not differ between the MRD-SR and MRD-IR groups (P = 0Á593), which had rates of 82Á4% (64Á9-91Á7%) and 68Á6% (30Á5-88Á7%), respectively ( Fig 1A) . Using results with a higher sensitivity of 10 À6 , the number of SR patients decreased to 23, and the number of IR patients increased to 26. As only one SR patient relapsed, the difference in 5-year LFS became statistically significant (P = 0Á005), with rates of 100% and 61Á7% (39Á1-78Á4%) for SR and IR patients, respectively (Fig 1B) .
Univariate and multivariate leukaemia-free survival analysis
This cohort was subjected to a univariate LFS analysis. Patients with positive NGS-MRD at day 33 [relative risk, RR (95% CI) = 2Á72 (0Á85-8Á68), P = 0Á091] had a marginally significantly poorer LFS (Table II and Fig 2A) . NGS-MRD at day 80 [RR (95% CI) = 7Á44 (2Á56-21Á60), P < 0Á001], 4-5 months [RR (95% CI) = 10Á24 (3Á374-31Á06), P < 0Á001], and 24 months [RR (95% CI) = 19Á26 (4Á974-74Á59), P < 0Á001] all correlated significantly with an inferior LFS. When patients were classified according to NGS-MRD positivity as low positive and high positive, either category at day 80 was a significantly poor risk factor for LFS [low positive: RR (95% CI) = 6Á63 (2Á01-21Á82), P = 0Á002; high positive: RR (95% CI) = 9Á40 (2Á32-38Á17), P = 0Á002] (Table II and Fig 2B) . Both low and high positivity at 4-5 months were significantly poor risk factors for LFS [low positive: RR (95% CI) = 10Á32 (3Á07-34Á70), P < 0Á001; high positive: RR (95% CI) = 10Á04 (2Á00-50Á34), P = 0Á005] (Table II and Fig 2C) .
To evaluate the effect of NGS-MRD on LFS at each time point, we assessed three multivariate Cox proportional hazard models. Both low and high positive NGS- MRD at day 80, 4-5 months and 24 months were confirmed as independent covariates predictive of a poor LFS (Table III) .
Clonal evolution
The unbiased detection of every CDR3 sequence enabled us to analyse the clonal evolution of leukaemic cells in each patient. For 15 patients whose relapse samples were available, we evaluated changes in the CDR3 sequences between the initial diagnosis and relapse (Fig 3) . One patient (UPN13) had no identifiable index clones at diagnosis. In 12 of 14 patients (86%) for whom CDR3 sequences were determined at diagnosis, the same CDR3 sequences were detectable at relapse. Clonal evolutions were observed in three patients. In UPN78 (Fig 3A) , three distinct leukaemic clones were observed at relapse. Two clones had the same CDR3 sequences as the index clones, whereas the third clone was detected at a lower frequency at diagnosis and during the treatment course. In UPN35 (Fig 3B) , an additional CDR3 sequence, which had not been detected at diagnosis or other : the 5-year LFS rates were 100% and 61Á7% (95% CI, 39Á1-78Á4%) in the MRD-SR and MRD-IR groups, respectively. earlier time points, appeared to have evolved at relapse. In UPN13 (Fig 3C) , although no index clones were detected at diagnosis, two leukaemic clones appeared at relapse. A retrospective analysis revealed that these clones were detectable at low frequencies (<10 À3 ). In UPN16, MRD was positive at the time of therapy cessation. However, the leukaemic clone was undetectable at relapse, suggesting a clonal evolution in which the detectable CDR3 sequences were lost.
Discussion
Monitoring MRD has become an indispensable practice in the treatment of paediatric B-cell ALL. However, the currently available methods have some technical limitations. Although NGS-MRD was developed in an attempt to overcome these limitations, several concerns have been raised regarding this novel method. One of the main concerns is the discrimination of leukaemia-specific IGH or TRG rearrangements from the normal clonal background. The average frequency of the most common IGH rearrangements in marrow aspirates of healthy individuals was 0Á08 AE 0Á04% of the total nucleated cells. Wu et al (2014) defined a frequency of >10% of all sequences as a threshold for leukaemia-specific sequences. Using this definition, the authors identified leukaemia-specific sequences in 92 of 99 (93%) patients enrolled in the Children's Oncology Group (COG) ALL trial. In contrast, other investigators set a cut-off of level of 5% (Faham et al, 2012; Ladetto et al, 2014; Pulsipher et al, 2015) . We arbitrarily used a cut-off level of 5Á0% for both IGH rearrangement and TRG rearrangement. We detected leukaemic CDR3 rearrangements in 72 of 79 patients (91%), which was comparable to the frequencies detected using sensitive RQ-PCR methods but inferior to those detected using FCM (Borowitz et al, 2008; Bruggemann et al, 2010; Gaipa et al, 2012) . The current sensitivities of RQ-PCR and FCM-MRD are as high as 10 À4 (Schrappe, 2012; van Dongen et al, 2015) ; however, higher sensitivities (up to 10 À6 ) have been reported for NGS-MRD (Faham et al, 2012) . Using test samples containing known numbers of leukaemic cells, we confirmed that the lowest limit of detection for our system was 10 À6 . In the COG study, NGS-MRD was compared with FCM-MRD in 91 patients with ALL at day 29 post-induction therapy day 80, the 5-year LFS rates were 90Á6% (76Á7-96Á4%), 37Á5% (8Á7-67Á4%) and 40Á0% (5Á2-75Á3%). (C) At 4-5 months, the 5-year LFS rates were 90Á2% (75Á9-96Á2%), 37Á5% (1Á1-80Á8%) and 21Á4% (1Á2-58Á6%).
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ª 2016 John Wiley & Sons Ltd (Wu et al, 2014) . There were no patients in whom MRD was detected by FCM but not NGS. Notably, the level of MRD was 10-to 100-fold lower with NGS-MRD than with FCM-MRD among patients subjected to both methods. Logan et al (2013) compared NGS-MRD with RQ-PCR-MRD in more than 400 samples from 40 patients with chronic lymphocytic leukaemia. Of these, 9Á2% of the evaluated samples were negative with RQ-PCR but positive with NGS. The general level of MRD in these samples was <10
À4
, demonstrating the improved sensitivity of NGS.
The improved sensitivity of NGS is expected to offer the potential advantage of accurate relapse and survival predictions after chemotherapy or HSCT. Pulsipher et al (2015) compared the predictive powers of NGS and FCM in 56 patients with B-cell ALL who underwent HSCT. Compared with FCM-MRD, NGS-MRD predicted both relapse and survival more accurately. The 2-year relapse probability was 0% among pre-HSCT NGS-MRD negative patients, and later translated to OS. The 2-year OS rates were 96% vs. 48% in pre-HSCT NGS-MRD negative versus positive patients. In contrast, the 2-year relapse probability and overall survival rates among pre-HSCT FCM-MRD negative patients were 16% and 77%, respectively.
In this study, we evaluated the prognostic value of NGS-MRD for consecutive patients treated according to a uniform ALL protocol, and retrospectively analysed the prognostic value of NGS-MRD using cryopreserved samples collected from 79 patients. To assess whether a very low level of NGSdetected MRD is useful for predicting clinical outcomes, we divided patients into low positive and high positive groups according to NGS-MRD findings. In both univariate and multivariate analyses, both high and low positive NGS-MRD results were significantly associated with a poor outcome. NGS-MRD could therefore identify a greater number of patients at a high risk of relapse who might be candidates for HSCT and novel alternative therapies (Maude et al, 2014; Topp et al, 2014) .
Previous studies assessed the most relevant monitoring time points among multiple follow-up points (CoustanSmith et al, 1998; van Dongen et al, 1998) . These studies found that MRD measurements during the first 3 months of treatment were the most informative for patient risk stratification. In the COG study, bone marrow FCM-MRD at day 29 was the most significant prognostic variable in a multivariate analysis (Borowitz et al, 2008) . Day-15 bone marrow FCM-MRD was also a powerful predictor of relapse in the AIEOP study (Basso et al, 2009 ). However, we could not reproduce the clinical impact of MRD at day 33 in our study, as neither low nor high MRD positivity at day 33 was a significant risk factor for poor LFS in the univariate and multivariate analyses. This difference might be attributed to both the sensitivity of MRD detection and the low statistical power of our study resulting from the small number of patients. Previous studies included at least 151 patients with MRD data at day 33 (Cave et al, 1998) . The number of patients used in the current study was relatively limited (55 patients with day-33 MRD data), which was too small to negate the null hypothesis. However, the trend was toward patients with MRD having greater risk of relapse (P = 0Á096). Therefore, we consider that the results of the current study are consistent with those of previous reports of FCM or real-time PCR MRD.
In the AIEOP-BFM studies, day-33 and day-78 bone marrow RQ-PCR-MRD values were used for risk stratification (Flohr et al, 2008) . We therefore classified our patients according to those criteria. Differences in LFS between the SR and IR groups were more efficiently discriminated using low and high positive MRD results, rather than high positive results alone. At day 80, 5 of 9 patients with low positive MRD and 3 of 7 patients with high positive MRD had relapsed. Our results suggest that the high sensitivity of NGS-MRD helps to identify high-risk patients more accurately.
Given the rarity of a positive MRD, clinical trials of B-cell ALL have not recommended systemic monitoring in later phases (Coustan-Smith et al, 1998; van Dongen et al, 1998) . Our study showed that the incidence of positive MRD and relapse rates were comparable between day 80 and 4-to 5-month time points. Furthermore, only one patient among the 49 with MRD-negative results at day 80 became MRD positive at 4-5 months. From these results, we conclude that MRD monitoring at 4-5 months may be unnecessary for patients who are MRD-negative at day 80. However, 6 of 8 patients with a positive MRD result on both day 80 and 4-5 months relapsed. In contrast, only 1 of 4 patients with a positive MRD on day 80 but a negative result at 4-5 months relapsed. MRD re-examination at 4-5 months may therefore be justified for patients with a positive MRD result at day 80. Moreover, all four patients with a positive MRD result at 24 months relapsed shortly after this MRD detection time point. HSCT should therefore be indicated for these patients because any MRD positivity at a later time point is predictive of a high incidence of relapse and is related to a poor outcome. Compared with RQ-PCR, NGS has the advantage of detecting clonal evolution during the course of disease, thus abrogating the risk of false-negative results. In the current study, the incidence of clonal evolution at relapse was not particularly high. The same leukaemic clones appeared in 12 of 14 relapsed patients. Even among the four patients who experienced late relapses following therapy cessation, the index and relapsed clones had the same CDR3 sequences. Our data suggest that Disclosure of conflict of interest S. Kojima was supported by a grant from Sanofi K.K. The other authors report no potential conflicts of interest.
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